A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503522-40-01

Acronym

ANB032-201

Enrollment

Registered

2024-03-13

Start date

2024-04-10

Completion date

2024-12-11

Last updated

2024-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

Proportion of subjects who achieve ≥ 75% reduction (improvement) from Baseline in EASI (EASI-75) at Week 14

Interventions

DRUGALCLOMETASONE

DRUGHYDROCORTISONE

DRUGPlacebo solution for injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of subjects who achieve ≥ 75% reduction (improvement) from Baseline in EASI (EASI-75) at Week 14	—

Countries

Czechia, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026